NASDAQ · CGEN
Compugen Ltd.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CGEN: Nov 09, 2026
Compugen Ltd. Ordinary Shares is expected to report earnings on 11/09/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.08. The reported EPS for the same quarter last year was $-0.07.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.08 | $-0.06 | $-0.10 | 3 |
| Dec 2026 | $-0.05 | $0.02 | $-0.10 | 3 |
| Mar 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Jun 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · Zacks · The Motley Fool · RTTNews- MarketBeat · Oct 5, 5:02 PM EDTCompugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor TargetsCompugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event. President and Chief
- Zacks · Aug 31, 12:00 PM EDTAll You Need to Know About Compugen (CGEN) Rating Upgrade to BuyCompugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks · Aug 21, 9:40 AM EDTAre Medical Stocks Lagging Compugen (CGEN) This Year?Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
- The Motley Fool · Aug 10, 9:44 PM EDTCompugen (CGEN) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 3, 10:04 AM EDTCompugen Q2 Earnings Call HighlightsCompugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029. President and Chief Executive Officer Eran
- Zacks · Aug 3, 8:05 AM EDTCompugen (CGEN) Reports Q2 Loss, Misses Revenue EstimatesCompugen (CGEN) delivered earnings and revenue surprises of 0.00% and -3.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · May 18, 10:41 AM EDTCompugen Q1 Net Loss Expands; On Track For Interim Analysis Of COM701 MAIA-ovarian Trial ;Stock Up(RTTNews) – Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company, reported financial results for the first quarter of 2026 and provided updates for its investigational candidates.
- MarketBeat · May 18, 10:08 AM EDTCompugen Q1 Earnings Call HighlightsCompugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partner
- Zacks · May 18, 9:00 AM EDTCompugen (CGEN) Reports Q1 Loss, Lags Revenue EstimatesCompugen (CGEN) delivered earnings and revenue surprises of -9.14% and -16.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- NASDAQ.com · May 15, 4:00 PM EDTPre-Market Earnings Report for May 18, 2026 : BIDU, RYAAY, RNW, IQ, CGEN, DUOT, NRXPThe following companies are expected to report earnings prior to market open on 05/18/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Baidu, Inc. (BIDU)is reporting for the quarter ending March 31, 2026. The internet services company's consensus e
- Zacks · May 15, 8:15 AM EDTBioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue EstimatesBioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +8.48% and -28.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 14, 7:40 AM EDTAdherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue EstimatesAdherex Technologies (FENC) delivered earnings and revenue surprises of +157.14% and +8.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Compugen Ltd. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.